Inclusion Criteria : 
  -  Children and adolescents who are diagnosed with pediatric chronic severe plaque psoriasis . 
  -  Prior to participating in the study , adalimumab treatment was determined according to clinical judgement of the physician . 
  -  Participants ( or legal representative ) who voluntarily agreed to participate in this study and signed informed consent . 
Exclusion Criteria : 
  -  Participants with contraindication to adalimumab as listed in the approved Korean label . 
  -  Participants with prior treatment with adalimumab .